Cancer Research

Chocolate And Cholesterol- At Some Point It's Okay To Call B.S.

John Erdman, a University of Illinois professor of food science and human nutrition who also chairs the Mars, Inc. Scientific Advisory Council and has received millions in funding from Mars, Inc., recognizes that taking money from a candy bar company (Mars ...

Article - Hank Campbell - Feb 14 2009 - 11:28pm

TopoTarget Successfully Buys Back Full Control Of Belinostat

COPENHAGEN, April 22 /PRNewswire/--- Consolidates the Global Rights for the Product- TopoTarget Successfully Buys Back Full Control of Belinostat, Consolidating the Global Rights for the Product- TopoTarget Acquires US & RoW Rights From CuraGen Corpor ...

Article - Anna Ohlden - Apr 22 2008 - 4:31am

Have We Stopped Living Longer?

A new study has found that between 1983 and 1999, the death rate in women increased in a large number of the worst-off counties in the US, primarily because of chronic diseases related to smoking, high blood pressure, and obesity. As a result of this stagn ...

Article - News Staff - Apr 22 2008 - 9:39am

Romark Announces Presentation Of New Data For Nitazoxanide In Chronic Hepatitis C At EASL 2008

MILAN, Italy, April 23 /PRNewswire/--- Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy and New Insights into Mechanism of Action of Nitazoxanide Romark Laboratories, a privately held biopharmaceutical company, today announced t ...

Article - Anna Ohlden - Apr 23 2008 - 1:31am

4SC AG Announces Change In The Supervisory Board

PLANEGG-MARTINSRIED, Germany, April 24 /PRNewswire/-- The Martinsried-based drug discovery and development company 4SC AG (Frankfurt, Prime Standard: VSC) announced today that the current Supervisory Board members Dr. Robert B. O'Connell and Dr. Bria ...

Article - Anna Ohlden - Apr 24 2008 - 3:31am

Nventa Completes Safety Evaluation On Final Cohort In HspE7 Phase 1 Cervical Dysplasia Trial

SAN DIEGO, April 24 /PRNewswire/--- HspE7 Phase 2 Trial for Cervical Dysplasia to Begin Mid-2008- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of the fourth and final cohort of p ...

Article - Anna Ohlden - Apr 24 2008 - 2:31pm

Data Suggests Promising Overall Survival And Progression-Free Survival With VARGATEF(TM) (BIBF 1120)

INGELHEIM, Germany, April 25 /PRNewswire/--- For non-US Healthcare Media- Abstract # 163O. von Pawel. Proffered Papers 6- Advanced NSCLC- Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented ...

Article - Anna Ohlden - Apr 25 2008 - 10:31am

Basic Science Discoveries Yield Progress In Hepatology

MILAN, April 26 /PRNewswire/-- At today's sessions of the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), experts reported advances in basic research that have important implications for the eventual treatment of pe ...

Article - News Staff - Apr 26 2008 - 12:20am

New Pegasys Data Show Hepatitis B Patients Achieve Highly Positive Treatment Response That Comes As Close To A Cure As Possible

BASEL, Switzerland, April 26 /PRNewswire/--- No Nucleoside/Nucleotide Analogue Treatments Have Shown Similar Results New data revealed today show that a significant number of patients with chronic hepatitis B virus infection who received PEGASYS(R) (pegin ...

Article - Anna Ohlden - Apr 26 2008 - 2:31am

Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response In Phase IIa S

BASEL, Switzerland, April 26 /PRNewswire/--- R1626 Also Shows a High Barrier to the Development of Resistance Roche's investigational treatment for hepatitis C, R1626, has shown an impressive end-of-treatment response rate when given in combination w ...

Article - Anna Ohlden - Apr 26 2008 - 11:31am